ArticleJournal of translational internal medicine2024

Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial.

Xiying Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.